Difference between revisions of "Fotemustine (Muphoran)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
m |
||
| Line 9: | Line 9: | ||
**[[Uveal melanoma]] | **[[Uveal melanoma]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *1989-04-14: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Muphoran, Mustophoran | *'''Brand names:''' Muphoran, Mustophoran | ||
| Line 21: | Line 23: | ||
[[Category:Uveal melanoma medications]] | [[Category:Uveal melanoma medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 1989]] |
Revision as of 11:56, 11 June 2023
Mechanism of action
From the NCI Drug Dictionary: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
Diseases for which it is used
History of changes in EMA indication
- 1989-04-14: EURD
Also known as
- Brand names: Muphoran, Mustophoran